Brief: Wuxi XDC Enters Strategic Collaboration With Earendil Labs
27/02/2026 11:47
Feb 27 (Reuters) - WuXi XDC Cayman Inc 2268.HK: WUXI XDC ENTERS STRATEGIC COLLABORATION WITH EARENDIL LABS ON WUXITECAN-2 PAYLOAD-LINKER TECHNOLOGY PLATFORM WUXI XDC CAYMAN INC - GRANTS EXCLUSIVE LICENSE TO EARENDIL LABS FOR WUXITECAN-2 TECHNOLOGY WUXI XDC CAYMAN INC - DEAL VALUE COULD REACH $885 MILLION INCLUDING MILESTONE PAYMENTS WUXI XDC CAYMAN INC - CO ELIGIBLE FOR TIERED ROYALTIES ON ADC SALES UPON COMMERCIALIZATION ((Reuters.Briefs@thomsonreuters.com;))
Recent news on WuXi XDC Cayman
See all newsBrief: Wuxi Apptec Announces Disposal Of 53.5 Mln Shares In Wuxi XDC Via Block Trade
HK-listed WuXi XDC hits 10-month peak on solid first-half results
Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition
Brief: WuXi XDC Cayman Posts H1 Revenue Of RMB3,701.4 Million
WuXi XDC climbs on share purchases under company scheme